Effectiveness and Safety of Different Estradiol Regimens in Transgender Females: A Randomized Controlled Trial
Journal of the Endocrine Society · 01.07.2024 · 8 (8)
DOI: 10.1210/jendso/bvae108 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the Endocrine Society, online erschienen am 12.06.2024. Verfasst von Samuel Cortez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Endocrinology, Diabetes, and Metabolism, Washington University School of Medicine in St. Louis, St. Louis, MO 6…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Background
A goal of gender-affirming hormone therapy (GAHT) for transgender women is to use estradiol to suppress endogenous production of testosterone. However, the effects of different estradiol regimens and route of administration on testosterone suppression is unknown. This is the first open-label randomized trial comparing different GAHT regimens for optimal estradiol route and dosing.
Objective
To evaluate 1 month and 6 months testosterone suppression <50 ng/dL with pulsed (once- or twice-daily sublingual 17-beta estradiol) and continuous (transdermal 17-beta estradiol) GAHT.
Methods
This study was conducted at an outpatient adult transgender clinic. Thirty-nine transgender women undergoing initiation of GAHT were randomly assigned to receive either once-daily sublingual, twice-daily sublingual, or transdermal 17-beta estradiol. All participants received spironolactone as an antiandrogen. Doses were titrated at monthly intervals to achieve total testosterone suppression <50 ng/dL.
Results
Transdermal 17-beta estradiol resulted in more rapid suppression of total testosterone, lower estrone levels, with no differences in estradiol levels when compared to once-daily and twice-daily sublingual estradiol. Moreover, there was no difference in the mean estradiol dose between the once-daily and twice-daily sublingual 17-beta estradiol group.
Conclusion
Continuous exposure with transdermal 17-beta estradiol suppressed testosterone production more effectively and with lower overall estradiol doses relative to once or twice daily sublingual estradiol. Most transgender women achieved cisgender women testosterone levels within 2 months on 1 or 2 0.1 mg/24 hours estradiol patches. Given no difference between once- or twice-daily sublingual estradiol, pulsed 17-beta estradiol likely provides no benefit for testosterone suppression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Endocrinology, Diabetes, and Metabolism, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
- Washington University School of Medicine in St. Louis, St. Louis,, MO 63110, USA.
- Department of Medicine, Division of Endocrinology, Diabetes, and Lipid Metabolism, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
- Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
- Department of Pediatrics, Division of Hematology/Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
- Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
ORCID-Profile: Samuel Cortez
Förderung
- NCATS NIH HHS
Zitieren
APA
Cortez, S., Moog, D., Lewis, C., Williams, K., Herrick, C. J., Fields, M. E., Gray, T., Guo, Z., Nicol, G., & Baranski, T. (2024). Effectiveness and Safety of Different Estradiol Regimens in Transgender Females: A Randomized Controlled Trial. Journal of the Endocrine Society, 8(8). https://doi.org/10.1210/jendso/bvae108
Vancouver
Cortez S, Moog D, Lewis C, Williams K, Herrick CJ, Fields ME, et al. Effectiveness and Safety of Different Estradiol Regimens in Transgender Females: A Randomized Controlled Trial. Journal of the Endocrine Society. 2024;8(8). doi:10.1210/jendso/bvae108
BibTeX
@article{Cortez2024,
author = {Cortez, Samuel and Moog, Dominic and Lewis, Christopher and Williams, Kelley and Herrick, Cynthia J and Fields, Melanie E and Gray, Teddi and Guo, Zhaohua and Nicol, Ginger and Baranski, Thomas},
title = {Effectiveness and Safety of Different Estradiol Regimens in Transgender Females: A Randomized Controlled Trial},
journal = {Journal of the Endocrine Society},
year = {2024},
volume = {8},
number = {8},
doi = {10.1210/jendso/bvae108}
}
EUVIMED